A Significant Role of Nontypeable Haemophilus influenzae in Acute Otitis Media in Bulgarian Children

Abstract

Objective We conducted a study on Haemophilus influenzae isolates recovered from children with acute otitis media (AOM). We aimed to establish the distribution of noncapsulated (also known as nontypeable Haemophilus influenzae [NTHi]) and encapsulated H. influenzae in the study population, and the antimicrobial susceptibilities of the isolates.

Methods We collected 113 nasopharyngeal swabs and 91 middle ear fluids/otorrhea specimens from patients up to 9 years of age with AOM. Of these, 26.1% (n = 53) were culture-positive for H. influenzae. Only one episode of AOM was included per patient. Conventional tests and rapid panel Neisseria/Haemophilus panel were used for the identification of the isolates. Detection of encapsulated and noncapsulated strains was done by polymerase chain reaction (PCR) for bexA gene. PCR-serotyping was performed for capsule types: “a” and “f.” Biotypes were assigned based on the indole, urease, and ornithine decarboxylase activity. Susceptibility testing was performed according to the criteria of European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Results Capsule determination showed that 96.2% of H. influenzae isolates responsible for “mild” and “severe” AOM cases in children were NTHi. Biotype I was predominantly associated with AOM isolates. Capsule types “a” and “c” were found in two isolates. Antibiotic resistance was found in 39.6% of the isolates. The highest resistance rate was for trimethoprim-sulfamethoxazole (37.7%). About 20.7% of isolates were ampicillin-resistant: 5.6% expressed a β-lactamase, and 15.1% had a β–lactamase-negative ampicillin-resistant phenotype.

Conclusion The current prevalence rates of nonsusceptible H. influenzae to ampicillin appear to be low among AOM. NTHi is an emergent pathogen in AOM cases. Ongoing observations are needed about how NTHi colonizes, survives, and evolves into a leading causative agent of H. influenzae diseases.

Keywords

nontypeable H. influenzae - acute otitis media - PCR-serotyping - antimicrobial resistance

Publication History

Received: 12 October 2022

Accepted: 26 January 2023

Article published online:
20 March 2023

• References

• 1 Gilsdorf JR. What the pediatrician should know about non-typeable Haemophilus influenzae. J Infect 2015; 71 (Suppl. 01) S10-S14
• 2 Clementi CF, Murphy TF. Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol 2011; 1: 1
• 3 Brandileone MC, Zanella RC, Almeida SCG. et al; Pneumococcal Carriage Study Group. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine 2016; 34 (46) 5604-5611
• 4 Wen S, Feng D, Chen D, Yang L, Xu Z. Molecular epidemiology and evolution of Haemophilus influenzae. Infect Genet Evol 2020; 80: 104205 DOI: 10.1016/j.meegid.2020.104205.
• 5 Amina Danishyar A, Ashurst JV. Acute Otits Media. NCBI Bookshelf: Stat Pearls Internet; 2022
• 6 Jinhage M, Hermansson A, Gisselsson-Solén M. Nasopharyngeal cultures in children with AOM - a retrospective study on bacteriological findings and impact on management. Int J Pediatr Otorhinolaryngol 2021; 149: 110848 DOI: 10.1016/j.ijporl.2021.110848.
• 7 van Ketel RJ, de Wever B, van Alphen L. Detection of Haemophilus influenzae in cerebrospinal fluids by polymerase chain reaction DNA amplification. J Med Microbiol 1990; 33 (04) 271-276
• 8 Falla TJ, Crook DW, Brophy LN, Maskell D, Kroll JS, Moxon ER. PCR for capsular typing of Haemophilus influenzae. J Clin Microbiol 1994; 32 (10) 2382-2386
• 9 European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 12.0, valid from 2022–01–01
• 10 Jalalvand F, Riesbeck K. Update on non-typeable Haemophilus influenzae-mediated disease and vaccine development. Expert Rev Vaccines 2018; 17 (06) 503-512
• 11 Leach AJ, Mulholland EK, Santosham M. et al. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial. BMC Pediatr 2021; 21 (01) 117 DOI: 10.1186/s12887-021-02552-z.
• 12 Sunakawa K, Takeuchi Y, Iwata S. [Nontypeable Haemophilus influenzae (NTHi) epidemiology]. Kansenshogaku Zasshi 2011; 85 (03) 227-237
• 13 Duell BL, Su Y-C, Riesbeck K. Host-pathogen interactions of nontypeable Haemophilus influenzae: from commensal to pathogen. FEBS Lett 2016; 590 (21) 3840-3853
• 14 Cerquetti M, Giufrè M. Why we need a vaccine for non-typeable Haemophilus influenzae. Hum Vaccin Immunother 2016; 12 (09) 2357-2361
• 15 Vermee Q, Cohen R, Hays C. et al. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis 2019; 19 (01) 44 DOI: 10.1186/s12879-018-3657-9.
• 16 Lecrenier N, Marijam A, Olbrecht J, Soumahoro L, Nieto Guevara J, Mungall B. Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children. Expert Rev Vaccines 2020; 19 (03) 247-265
• 17 Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines 2017; 16 (07) 1-14
• 18 Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008; 46 (05) 726-731
• 19 Khan MN, Ren D, Kaur R, Basha S, Zagursky R, Pichichero ME. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae. Expert Rev Vaccines 2016; 15 (07) 863-878